An interventional study of 15 ml Bupivacaine Hcl 0.25% injection and 20 mL bupivacaine 0.25% injection in Hip Osteoarthritis, Osteonecrosis of the Femoral Head and Avascular Necrosis of Femur Head, sponsored by Ataturk University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Ataturk University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Osteoarthritis, Hip with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Osteoarthritis, Hip · Turkey.
Among the 27 studies in Osteoarthritis, Hip with a site in Turkey, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 21st registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →5 of the 27 studies in Osteoarthritis, Hip with a site in Turkey are open now. Recruiting first, the newest first:
Konya Meram State Hospital · Sites in Turkey
Ages 18+
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Bahattin Kemah · Sites in Turkey
Ages 30+
Dokuz Eylul University · Sites in Turkey
Ages 18–75
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 90 across 458 interventional studies indexed under Osteoarthritis, Hip.
Median enrollment 60 across the 18 interventional studies, 60 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 27 has an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
Ataturk University has 1 study filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Hip with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07683663Dokuz Eylul UniversityQIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty | 2026-12-01 |
| NCT07458360Konya Meram State HospitalFRONT Block for Quality of Recovery After Total Hip Arthroplasty | 2026-12-05 |
| NCT07360093Ankara City Hospital BilkentPENG Block & PENG PRF | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Osteoarthritis, Hip with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the clinic, total hip arthroplasty is a frequently performed surgical procedure that often results in moderate to severe postoperative pain. Multimodal analgesia approaches are commonly preferred for managing this pain, and in recent years, nerve blocks targeting pelvic innervation have become increasingly prominent. Among these, the Pericapsular Nerve Group (PENG) block has gained attention for providing effective analgesia by targeting the nerves responsible for the anterior innervation of the hip capsule. However, when used alone, the PENG block may be insufficient for controlling posterior hip pain and may not provide complete analgesia.
In this context, adding blocks targeting the superior cluneal nerve and the superior gluteal nerve-both of which contribute to the sensory innervation of the posterior hip region-has been proposed to enhance the analgesic effect when combined with the PENG block. Superior cluneal and superior gluteal nerve blocks have recently been described in anatomical and clinical studies, and by affecting the structures contributing sensory input to the posterior hip capsule, they hold significant potential for improving pain management.
In this study, the investigators aimed to evaluate the contribution of superior cluneal and superior gluteal nerve blocks, when added to the PENG block, to perioperative analgesia in patients undergoing total hip arthroplasty. The investigators sought to comparatively investigate whether this combination offers superior outcomes compared with the PENG block alone. It was hypothesized that combined nerve blocks may provide similar or improved recovery scores, lower pain scores, reduced opioid consumption, and enhanced analgesic efficacy without affecting the degree of motor blockade.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be brought to the operating room one hour before surgery, and no premedication will be administered prior to their arrival. Before performing the PENG block, patients will be placed in the supine position. The ultrasound probe will be positioned in the transverse plane medial and caudal to the anterior superior iliac spine, and the anterior inferior iliac spine, iliopubic eminence, and psoas tendon will be identified. Using an in-plane technique, the needle will be advanced from lateral to medial and positioned between the psoas tendon and the periosteum. After negative aspiration, 15 mL of 0.25% bupivacaine will be administered.
Drug: 15 ml Bupivacaine Hcl 0.25% injection · Drug: 20 mL bupivacaine 0.25% injection
All patients will receive a PENG block, and in addition: The superior cluneal nerve block will be performed at the level of the posterior iliac crest under ultrasound guidance, along the course of the nerve, using 10 mL of 0.25% bupivacaine. The superior gluteal nerve block will be administered in the lateral decubitus position under ultrasound guidance, with 10 mL of 0.25% bupivacaine injected between the gluteal muscles along the trajectory of the nerve.
Drug: 20 mL bupivacaine 0.25% injection
For PENG Block, 15 mL of 0.25% bupivacaine will be administered.
After performing PENG; 10 mL of 0.25% bupivacaine will be administered for each superior cluneal nerve block and superior gluteal nerve block
QoR-15 (Quality of Recovery-15) questionnaire
The primary outcome measure will be the QoR-15 (Quality of Recovery-15) questionnaire administered at the 24th postoperative hour. QoR-15 is a validated 15-item short survey assessing patients' postoperative physical comfort, emotional state, level of independence, pain control, and overall well-being. The total score obtained will be used to compare the overall quality of recovery between groups. The same questionnaire will be repeated at the 48th postoperative hour.
Time frame: 24th and 48th postoperative hour
Quadriceps Motor Block Assessment
Motor block will be assessed using the following 3-point scale: 0 = Normal strength (dorsiflexion against gravity and resistance) 1. = Paresis (dorsiflexion against gravity only, not against resistance) 2. = Paralysis (dorsiflexion not possible)
Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.
Motor Block Assessment at the Tibialis Anterior Muscle for the Sciatic Nerve
Motor block will be assessed using the following 3-point scale: 0 = Normal strength (dorsiflexion against gravity and resistance) 1. = Paresis (dorsiflexion against gravity only, not against resistance) 2. = Paralysis (dorsiflexion not possible)
Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.
Fentanyl consumption
Fentanyl consumption will be recorded via the PCA device during the postoperative intervals of 0-4, 4-8, and 8-24 hours. Total opioid consumption will be calculated at the 24th postoperative hour.
Time frame: The first 24 postoperative hours
VAS pain scores
VAS pain scores will be assessed at the 1st, 2nd, 4th, 8th, 12th, and 24th postoperative hours, both at rest and during movement. The region where the patient experiences the most intense pain will be recorded as either the anterior or posterior hip.
Time frame: The first 24 postoperative hours
Started Sep 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.
Of 201 non-industry interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 11 months is below that.
Counting every sponsor, half of 227 studies reached it within 29 months; a quarter within 14 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine